Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
ADAditxt, Inc. logo

Aditxt, Inc. (ADTX)

Other OTC · Currency in USD
$0.00 ▲ +0.00 (+66.67%)
At close: Oct 23, 4:00 PM ET. Market closed.

Summary

Previous Close
$0.00
Open
$0.00
Day's Range
$0.00 – $0.00
52 Week Range
$0.00 – $5,833.51
Volume
9,762,594
Avg. Volume
296,901,881
Market Cap
$997.98K
Beta (5Y Monthly)
0.93
PE Ratio (TTM)
--
EPS (TTM)
-$2,575.18
Earnings Date
Dec 2, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$1,280.00

Profile: Aditxt, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
26
CEO
Jeffrey Busch
Website
aditxt.com

Aditxt, Inc. is a biotechnology firm dedicated to advancing immune system health through innovative mapping and reprogramming techniques. The company's developments include AditxtScore, a platform designed to empower individuals by providing insights into their immune profiles for better management and informed awareness of immune system attacks or dysfunctions. Aditxt also pioneers Apoptotic DNA Immunotherapy, a nucleic acid-based solution that emulates the body's inherent mechanisms for developing self-tolerance to its own tissues.

Earnings

Next report: Wed, Dec 2, 2026
EPS estimate -$24,408,000,000.00 · Revenue est. $1.00M
DateEst.Actual
May 20, 2026-$2,245,536,000.00-$2.06Beat
Feb 25, 2026-$6,443,712.00-$1.48Beat
Nov 17, 2025-$6,687,792.00-$158.16Beat
Aug 14, 2025-$6,565,752.00-$847.67Beat
May 15, 2025-$8,127,864.00-$1,995.09Beat
Apr 14, 2025-$72,760,248.00-$10,910,376.00Beat

Analyst view

Consensus price target
$1,280.00 ▲ +127,999,900.0%
Range $1,280.00 – $1,280.00
Rating: Buy
Buy 50% · Hold 50% · Sell 0%

Get free alerts on ADTX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.